======= NCAPD2 ======= == Gene Information == * **Official Symbol**: NCAPD2 * **Official Name**: non-SMC condensin I complex subunit D2 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9918|9918]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q15021|Q15021]] * **Interactions**: [[https://thebiogrid.org/search.php?search=NCAPD2&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20NCAPD2|Open PubMed]] * **OMIM**: [[https://omim.org/entry/615638|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Regulatory subunit of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes. The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases. May target the condensin complex to DNA via its C-terminal domain. {ECO:0000269|PubMed:11136719}. |Cnd1| |Cnd1 N| |condensin core heterodimer| |nuclear condensin complex| |meiotic chromosome condensation| |condensin complex| |condensed chromosome, centromeric region| |mitotic chromosome condensation| |condensed chromosome| |nuclear chromosome| |chromosome separation| |chromosome condensation| |chromosome organization involved in meiotic cell cycle| |mitotic sister chromatid segregation| |histone binding| |sister chromatid segregation| |mitotic nuclear division| |meiotic cell cycle process| |DNA packaging| |nuclear chromosome segregation| |meiotic cell cycle| |chromosome segregation| |nuclear division| |DNA conformation change| |organelle fission| |chromatin binding| |cell division| |mitotic cell cycle process| |mitotic cell cycle| |cell cycle process| |chromosome organization| |cell cycle| |reproductive process| |reproduction| |membrane| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-2.33| |[[:results:exp210|LB-100 2μM R05 exp210]]|-2.17| |[[:results:exp513|ONC212 0.15μM R08 exp513]]|-1.97| |[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-1.91| |[[:results:exp69|Deguelin 0.05μM R02 exp69]]|-1.85| |[[:results:exp505|ML-792 0.2μM R08 exp505]]|-1.83| |[[:results:exp333|All-trans-Retinoic-Acid 8μM R07 exp333]]|-1.81| |[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|-1.76| |[[:results:exp93|DABN racemic mixture R03 exp93]]|2.21| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 347/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|10/28| |blood|21/28| |bone|14/25| |breast|21/33| |central nervous system|20/56| |cervix|2/4| |colorectal|6/17| |esophagus|3/13| |fibroblast|1/1| |gastric|10/15| |kidney|10/21| |liver|9/20| |lung|36/75| |lymphocyte|6/14| |ovary|9/26| |pancreas|9/24| |peripheral nervous system|10/16| |plasma cell|9/15| |prostate|1/1| |skin|10/24| |soft tissue|1/7| |thyroid|0/2| |upper aerodigestive|10/22| |urinary tract|9/29| |uterus|3/5| == Essentiality in NALM6 == * **Essentiality Rank**: 708 * **Expression level (log2 read counts)**: 8.76 {{:chemogenomics:nalm6 dist.png?nolink |}}